Clinical Scorecard: Assessing Arrhythmogenic Risk in Mitral Valve Prolapse Patients Using Cardiac Magnetic Resonance: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• MVP affects 2–3% of the general population with a low overall SCD incidence (0.1–0.4% per year) but a subgroup (AMVP) has higher arrhythmic risk.
• Cardiac magnetic resonance (CMR) is central for non-invasive arrhythmic risk stratification including assessment of LV size/function, MR severity, leaflet morphology, mitral annular disjunction, and late gadolinium enhancement.
• Systematic review and meta-analysis aim to identify CMR features discriminating patients with complex ventricular arrhythmias to guide monitoring and preventive strategies.

Guideline-Based Recommendations

Diagnosis

• Use CMR to assess left ventricular size and function, mitral regurgitation severity, leaflet length/thickness, mitral annular disjunction, curling, and late gadolinium enhancement in MVP patients.
• Incorporate clinical and ECG features such as syncope, T-wave inversion, QTc prolongation, and ventricular arrhythmia burden in risk stratification.

Management

• Tailor monitoring strategies including implantable loop recorders for high-risk MVP patients identified by CMR and clinical features.
• Consider preventive therapies such as beta-blockers and implantable cardioverter defibrillators in patients with arrhythmic MVP at elevated risk.

Monitoring & Follow-up

• Regular follow-up with imaging and arrhythmic profile assessment to detect progression or emergence of complex ventricular arrhythmias.
• Use of implantable loop recorders for continuous arrhythmia monitoring in selected high-risk patients.

Risks

• Recognize that MVP patients with mitral annular disjunction, bi-leaflet prolapse, longer anterior leaflet, and myocardial fibrosis (LGE) have increased risk of malignant ventricular arrhythmias and sudden cardiac death.
• Be aware of the low but significant risk of sudden cardiac death in the general MVP population, necessitating individualized risk assessment.

Patient & Prescribing Data

Patients with mitral valve prolapse undergoing cardiac magnetic resonance imaging for arrhythmic risk assessment

Identification of high-risk features on CMR can guide initiation of beta-blockers and consideration for implantable cardioverter defibrillator placement to prevent sudden cardiac death.

Clinical Best Practices

• Perform comprehensive CMR evaluation including LV size/function, MR severity, leaflet morphology, mitral annular disjunction, and late gadolinium enhancement in MVP patients.
• Integrate clinical, ECG, and imaging data for holistic arrhythmic risk stratification in MVP.
• Use systematic review evidence to inform individualized monitoring and preventive strategies in patients with arrhythmic MVP.
• Apply guideline-endorsed protocols for diagnosis and management to reduce sudden cardiac death risk.

References

• 2021 ESC/EACTS Guidelines for the management of valvular heart disease
• European Heart Rhythm Association (EHRA) expert consensus statement on arrhythmic mitral valve prolapse
• Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement
• Agency for Healthcare Research and Quality risk of bias guidelines